CHARLEMONT
Cancer Incidence by Sex, 1993 - 1997
Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR
Bladder, Urinary	<u>/</u>		Melanoma of Skin				
Male	0.88	1	NC*	Male	0.50	0	NC*
Female	0.25	0	NC*	Female	0.33	0	NC*
Total	1.13	1	NC*	Total	0.83	0	NC*
Brain and Other	Central N	ervous Syste	Multiple Myel	<u>oma</u>			
Male	0.27	0	NC*	Male	0.16	1	NC*
Female	0.20	0	NC*	Female	0.12	0	NC*
Total	0.47	0	NC*	Total	0.28	1	NC*
Breast				Non-Hodgkin's Lymphoma			
Male	0.06	0	NC*	Male	0.66	0	NC*
Female	4.34	9	207	Female	0.48	0	NC*
Total	4.40	9	205	Total	1.14	0	NC*
Cervix Uteri			Oral Cavity and Pharynx				
				Male	0.56	0	NC*
Female	0.27	0	NC*	Female	0.22	1	NC*
				Total	0.79	1	NC*
Colon / Rectum				<u>Ovary</u>			
Male	2.23	4	NC*				
Female	1.62	2	NC*	Female	0.52	0	NC*
Total	3.85	6	156				
Esophagus				Pancreas			
Male	0.32	0	NC*	Male	0.34	0	NC*
Female	0.08	0	NC*	Female	0.27	0	NC*
Total	0.41	0	NC*	Total	0.61	0	NC*
Hodgkin's Disea	<u>se</u>		Prostate				
Male	0.11	0	NC*	Male	5.55	4	NC*
Female	0.08	0	NC*				
Total	0.19	0	NC*				
Kidney and Rena	al Pelvis		Stomach				
Male	0.50	0	NC*	Male	0.38	0	NC*
Female	0.25	0	NC*	Female	0.17	0	NC*
Total	0.75	0	NC*	Total	0.55	0	NC*
<u>Larynx</u>				Testis			
Male	0.31	2	NC*	Male	0.14	0	NC*

0.07	0	NC*					
0.39	2	NC*					
			Thyroid				
0.36	1	NC*	Male	0.09	0	NC*	
0.23	0	NC*	Female	0.21	0	NC*	
0.59	1	NC*	Total	0.30	0	NC*	
Liver and Intrahepatic Bile Ducts				Uteri, Corpus and Uterus, NOS			
0.18	0	NC*					
0.06	0	NC*	Female	0.85	3	NC*	
0.23	0	NC*					
Lung and Bronchus				All Sites / Types			
2.87	3	NC*	Male	17.64	18	102	
1.73	3	NC*	Female	13.31	20	150	
4.60	6	130	Total	30.95	38	123	
	0.39 0.36 0.23 0.59 Erahepatic Bile 1 0.18 0.06 0.23 Onchus 2.87 1.73	0.39 2 0.36 1 0.23 0 0.59 1 crahepatic Bile Ducts 0.18 0 0.06 0 0.23 0 conchus 2.87 3 1.73 3	0.39 2 NC* 0.36 1 NC* 0.23 0 NC* 0.59 1 NC* crahepatic Bile Ducts 0.18 0 NC* 0.06 0 NC* 0.23 0 NC* conchus 2.87 3 NC* 1.73 3 NC*	0.39 2 NC* 1 NC* Male 0.23 0 NC* Female 0.59 1 NC* Total Crahepatic Bile Ducts Uteri, Corpus 0.18 0 NC* 0.06 0 NC* Female 0.23 0 NC* onchus All Sites / Tyle 2.87 3 NC* Male 1.73 3 NC* Female	0.39 2 NC* Thyroid 0.36 1 NC* Male 0.09 0.23 0 NC* Female 0.21 0.59 1 NC* Total 0.30 Uteri, Corpus and Uterus 0.18 0 NC* Female 0.85 0.23 0 NC* Female 0.85 onchus All Sites / Types 2.87 3 NC* Male 17.64 1.73 3 NC* Female 13.31	O.39 2 NC* Thyroid O.36 1 NC* Male O.09 0 O.23 0 NC* Female O.21 0 O.59 1 NC* Total O.30 O O.59 O.18 O.18 O.18 O.18 O.18 O.18 O.18 O.23 O.23 O.23 O.23 O.23 O.23 O.23 O.23 O.24 O.25 O.25 O.25 O.25 O.26 O.27 O.27 O.28 O.28 O.29 O.2	

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels